Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: Implications for therapy

Expert Review of Anticancer Therapy

Volumn 15, Issue 6, 2015, Pages 623-628

  Huss, Sebastian ^a   Elges, Sandra ^a   Trautmann, Marcel ^a   Sperveslage, Jan ^a   Hartmann, Wolfgang ^a   Wardelmann, Eva ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

BRAF; GIST; imatinib; KIT; NF1; PDGFRA; SDHA; SDHB; wild type

Indexed keywords

B RAF KINASE; DABRAFENIB; IMATINIB; K RAS PROTEIN; LINSITINIB; NEUROFIBROMIN; PLACEBO; SUCCINATE DEHYDROGENASE; SUNITINIB; ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

BRAF GENE; CANCER PROGNOSIS; CARNEY STRATAKIS SYNDROME; COMPLEX II DEFICIENCY; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; KIT GENE; KRAS GENE; LOSS OF FUNCTION MUTATION; NEUROFIBROMATOSIS TYPE 1; PARAGANGLIOMA; PATHOGENESIS; PDGFRA GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; TUMOR CLASSIFICATION; GASTROINTESTINAL STROMAL TUMORS; GENETICS; MUTATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMATINIB MESYLATE; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SUCCINATE DEHYDROGENASE;

EID: 84930460618     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1032941     Document Type: Review

References (51)

1. Huss S, Künstlinger H, Wardelmann E, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol 2013;26(7):1004-12
2. Gari M, Goodeve A, Wilson G, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105: 894-900
3. Care R, Valk P, Goodeve A, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003;121:775-7
4. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumor and mastocytosis. Gastroenterology 2005;129:1042-6
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23: 70-83
6. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3): iii21-6
7. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003;21:4342-9
9. Joensuu H, Eriksson M, Hartmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). JAMA 2011;307(12):1265-72
10. Dematteo R, Ballman K, Antonescu C, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373: 1097-104
11. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-95
12. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190-8
13. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010;21:1552-7
14. Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res 2014;20(23):6105-16.
15. Janeway KA, Pappo A. Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol 2012;34(Suppl 2):S69-72
16. Janeway KA, Kim SY, Lodish M, et al; Pediatric and Wild-Type GIST Clinic. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108(1):314-18
17. Italiano A, Chen J, Zhang L, et al. Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. Eur J Cancer 2012;48(17):3215-22
18. Agaram N, Wong G, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47(10):853-9.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
20. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
21. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133(1): 141-8
22. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009;62(7):613-16
23. Martinho O, Gouveia A, Viana-Pereira M, et al. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 2009;55(1):53-62
24. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013;4(2): 310-15
25. Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18(6):1769-76
26. Ricci R, Dei Tos AP, Rindi G. On the prevalence of KRAS mutations in GISTs. Virchows Arch 2013;463(6):847
27. Lasota J, Xi L, Coates T, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol 2013;26(11): 1488-91
28. Hechtman JF, Zehir A, Mitchell T, et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer 2014;54(3):177-84.
29. Zoller ME, Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79: 2125-31
30. Mussi C, Schildhaus H, Gronchi A, et al. Therapeutic consequences from molecular biology for GIST patients affected by neurofibromatosis type I. Clin Cancer Res 2008;14(14):4550-5
31. Nannini M, Astolfi A, Urbini M, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014;14:685.
32. Carney J, Stratakis C. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 2002;108:132-9
33. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010;19: 3011-20
34. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008;16(1):79-88
35. Miettinen M, Wang Z, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GIST: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GIST with predilection to young age. Am J Surg Pathol 2011;35:1712-21
36. Pantaleo M, Astolfi A, Indio V, et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011;103(12):983-7
37. Pantaleo M, Astolfi A, Urbini M, et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J of Hum Genet 2014;22:32-9.
38. McWhinney SR, Pasini B, Stratakis CA; International Carney Triad and Carney-Stratakis Syndrome Consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007; 357(10):1054-6
39. Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014; 21(4):567-77.
40. Carney JA, Sheps SG, Go VL, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296:1517-18
41. Carney JA. Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab 2009;94:3656-62
42. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009;266(1): 43-52
43. Zhang L, Smyrk T, Young WJ, et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010;34:53-6
44. Killian JK, Miettinen M, Walker RL, et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 2014;6(268):268ra177
45. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35(11):1712-21
46. Pantaleo MA, Lolli C, Nannini M, et al. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med 2014. [Epub ahead of print]
47. Debiec-Rychter M, Sciot R, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42(8):1093-103
48. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26(33):5352-9
49. Corless C, Ballman KV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010;28(15 Suppl):abstract 10006
50. von Mehren M, George S, Heinrich MC, et al. Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST). J Clin Oncol 2014; 32(5 Suppl):abstract 10507
51. Carney JA, Stratakis CA, Young WF Jr. Adrenal cortical adenomas: the fourth component of the Carney triad and an association with subclinical Cushing syndrome. Am J Surg Pathol 2013;37: 1140-9